Written question WQ99082

The NHS Wales Joint Commissioning Committee is responsible for maintaining the genomic test directory in accordance with recommended clinical practice. More information can be found at:

Genomics - NHS Wales Joint Commissioning Committee

The All-Wales Medical Genomics Service (AWMGS) provides access to health board clinical teams to genomic testing in line with the test directory. As it is established as a national service, delivering a national test directory, this helps to ensure equity for patients across Wales. More information on the services offered can be found at:

https://medicalgenomicswales.co.uk/index.php/en/

Health boards in Wales are responsible for offering genomic testing in line with recommended clinical practice, in this case the expert guidance from the National Institute for Health and Care Excellence on familial risk of breast cancer.

Overview | Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer | Guidance | NICE

And in the case of targeted therapies:

Overview | Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations | Guidance | NICE

Overview | Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy | Guidance | NICE

Overview | Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy | Guidance | NICE

AWMGS also works with other organisations in Genomics Partnership Wales and Health Education and Improvement Wales to develop a skilled, engaged and genomically aware workforce across NHS Wales.